Beta Bionics Receives FDA Clearance For Its Mint Pump That Requires No Recharging And Integrates With Industry-Leading Continuous Glucose Monitors; Lowers FY26 Sales Guidance From $131M-$136M To $121M-$126M Reflecting Potential Revenue Deferral Impact Of Up To $10M In Q4 As New Prospective iLet Users Could Choose To Await The Launch Of Mint